Nielsen Fernandez-Becker
Gastroenterology · Palo Alto, CANPI 1972678639
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,177 of the $1,879 with a category attached, or 62.6%. Adare Pharmaceuticals, Inc. accounts for 82.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $1,545 and has fallen 95.3% since, to $72 in 2025. That places this record below the midpoint for gastroenterology clinicians in CA, where the typical reported total is $1,790.
Across 11 payments — averaging $170.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Adare Pharmaceuticals, Inc.$2K
- Anx Robotica Corp$262
- Boston Scientific$43
- Mauna Kea Technologies, Inc.$29
Across 28 payments — averaging $9907.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Immunogenx, Inc.$180K
- Takeda Pharmaceuticals U.S.A., Inc.$76K
- Regeneron$21K
What the payments were for
- Travel & lodging$1,17763%
- Food & beverage$70337%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Adare Pharmaceuticals, Inc. | 6 | $1,545 |
| Anx Robotica Corp | 2 | $262 |
| Boston Scientific | 2 | $43 |
| Mauna Kea Technologies, Inc. | 1 | $29 |
How this compares
$1,879 in reported general payments places this provider in the 50th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 15 | $79,519 |
| CreonLipase/Protease/Amylase | 21 | $38,068 |
| MotegrityPrucalopride Succinate | 24 | $26,679 |
| LinzessLinaclotide | 38 | $25,774 |
| Omeprazole | 92 | $1,660 |
| Famotidine | 45 | $847 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 32 | $644 |
| Pantoprazole Sodium | 13 | $259 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 15 | $223 |
| Nortriptyline Hcl | 17 | $221 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 11 | $190 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Palo Alto
- David ShieldsPalo Alto$301K
- Tonya KaltenbachPalo Alto$269K
- Ryan McConnellPalo Alto$197K
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.